

References

I-180

1. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier CCTL019B2202, Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL (ELIANA); 2017 July 28 [cited 2017 Sept 15].
2. Maude , Frey N, Shaw P, et al. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. *N Engl J Med.* 2014;371:1507-1517.
3. MICROMEDEX®SOLUTIONS Compendia. 2018. Tisagenlecleucel.
4. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Tisagenlecleucel.
5. NCCN Drugs & Biologics Compendium™. Tisagenlecleucel. 2018. National Comprehensive Cancer Network (NCCN).
6. KYMRIA™ [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation. 5/2018.
7. KYMRIA™ [dossier]. East Hanover, NJ: Novartis Pharmaceuticals Corporation. 2018.
8. U.S. Food & Drug administration. FDA Briefing Document Oncologic Drugs Advisory Committee Meeting. BLA 125646 tisagenlecleucel. Available at: <https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/ucm566165.htm>. Accessed September 15, 2017.
9. Grupp S, Buechner J, Bittencourt H. Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/ Refractory Acute Lymphoblastic Leukemia [Abs 221]. *Blood.* 2016.
10. Buechner J, Grupp S, Maude S, et al. Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis [Abs S476]. *Haematologica.* 2017.
11. Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. *Science Translational Medicine.* 2017;1-12.
12. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with BCell Lymphoblastic Leukemia. *N Engl J Med.* 2018;378:439-48.
13. Crump M, Neelapu SS, Farooq U et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. *Blood.* 2017; 1800-1808.
14. Neelapu S, Locke F, Bartlett N, et al. SCHOLAR-1 versus ZUMA-1: A Standardized Comparison of Outcomes in Patients (Pts) with Refractory, Aggressive Non-Hodgkin Lymphoma (rNHL). *Clinical*

Lymphoma, Myeloma & Leukemia. 2017;S362-S363.

15. Neelapu S, Locke F, Bartlett N, et al. Axicabtagene ciloleucel (AXI-CEL; KTE-C19) in patients with refractory aggressive non-hodgkin lymphomas (nhl): primary results of the pivotal trial ZUMA-1. *Hematological Oncology*. 2017;28.
16. Delaware State Mandate; 18 DE Code, §§3338B and 3555B.
17. Yescarta™ [package insert]. Santa Monica, CA: Kite Pharma, Inc. 10/2017.
18. *Clinical Pharmacology Compendia*. [database online]. Tampa FL: Gold Standard, Inc. Axicabtagene Ciloleucel.